PMID: 18405250Apr 15, 2008Paper

Sinus bradycardia associated with daclizumab in liver transplant recipients: report of 3 cases

Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation
Adel Bassily-MarcusErnest Benjamin

Abstract

Daclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.